JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2013, Vol. 51 ›› Issue (3): 95-98.

• Articles • Previous Articles     Next Articles

Clinical analysis of recombinant human endostatin combined with gemcitabine and  cisplatin therapy in advanced non-small cell lung cancer

ALIMUJIANG·Stiwaerdi,  ZHANG Tao,  PATIGULI·Aerxiding, LIU Li   

  1. First Department of Internal Medicine, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, China
  • Received:2012-08-12 Online:2013-03-10 Published:2013-03-10

PDF (PC)

279

Abstract:

Objective   To investigate the clinical efficacy and adverse reactions of recombinant human endostatin (YH-16) in combination with gemcitabine and cisplatin (GP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods   80 cases of advanced NSCLC were randomly divided into the observation group (40 cases) and the control group (40 cases). The observation group were treated with YH-16 combined with GP, and the control group accepted GP. After 2 cycles of chemotherapy, the curative effect and adverse reactions were evaluated. The long-term efficacy of the two groups was evaluated during follow-up. Results  The clinical benefit rates in the observation group and the control group were 32.5% and 25.0% respectively, and the difference was statistically significant (P<0.05). But the long-term efficacy and adverse reactions in the two groups were similar (P>0.05). Conclusion   YH-16 in combination with GP in the treatment of advanced NSCLC improves the patient′s curative effect, but does not increase the incidence of adverse reactions.

Key words: Non-small cell lung cancer; Recombinant human endostatin; Gemcitabine; Cisplatin; Chemotherapy

CLC Number: 

  • R734.2
[1] XU Xiao-ya, BI Yu-li, JIANG Man, XU Ji-ying, ZHANG Peng-fei, HAN Ming-yong. Vascular endothelial growth factor (VEGF) promotes lung carcinoma metastasis via VEGFR1 in mouse model [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(11): 25-29.
[2] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(11): 108-110.
[3] TIAN Tian-tian1, LI Ji-sheng1, WANG Ya-wei1, MA Dao-xin2, WANG Xiu-wen1. Genistein exerts antitumor effects in small cell lung cancer H446 cells via suppressing the activity of FoxM1 pathway [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(06): 44-48.
[4] LIU Bing1， YU Zhuang1， HOU Xian-peng1， YAO Ru-yong2. Different expressions of EGFR and HER-3 genes in human lung adenocarcinoma cells and pemetrexed-resistant cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(5): 20-23.
[5] DONG Xue-li, MU Xiao-yan, LIU Qing-liang, SUN Jie. Effects of erlotinib combined with celecoxib on growth and angiogenesis of human lung cancer xenograft model [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(2): 49-52.
[6] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(10): 130-131.
[7] LIU Qing-liang1, MU Xiao-yan1, WANG-Jing2, CHI Xiang-yu2, ZHANG Min3, MA Wei-xia3. Inhibitory effects of RNA interference and Erlotinib by blocking epidermal
growth factor receptor pathway on the proliferation of A549 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 11-.
[8] FAN Heng-jian, ZHANG Yu-ke, XIAO Wei, ZHANG Yi, LI Hai-jun, WANG De-xiang. Changes of Treg and Th17 cells in the peripheral bloods of patients with
lung adenocarcinoma and their prognostic significance [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 73-78.
[9] WANG Ji-xia, LI Gui-xin, HUANG Yan, WANG Li-juan. Expressions and clinical significances of E1AF，MMP-7 and uPA in nonsmall cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(7): 109-.
[10] XU Tong-zhen, SUN Xue-fei, REN Dong-mei, YANG Guo-tao. Antiproliferation activity of luteolin and its role in combined chemotherapy on lung cancer A549 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(7): 50-54.
[11] LIU Hai-rong1， YU Jin-ming2， LI Yan1， LIANG Jing1， LIU Xiao-lin1. Study of the relationship between ER， PR， C-erB-2 and
bone metastasis of  lung adenocacinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(4): 91-.
[12] MA Yu-hua1,2, ZHENG Yan3, JIA Yan-fei3, WANG Yun-shan3. GFR and DEC1 protein co-expression promotes lymph node
metastasis in lung adenocarcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(3): 24-28.
[13] SUN Xue-fei, PEI Yan-tao,YIN Qiu-wei, YANG Guo-tao, WANG De-jiang. Inhibitory effect of Radix Actinidiae extractive on transplantation
tumor of the lung cancer cell line A549 in nude mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(2): 38-42.
[14] LI Peng, LIU Qi， HAN Ming-yong. PET/CT，CEA and CYFRA21-1 predicting the therapeutic effect of targeted drug on non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(1): 129-132.
[15] JIANG Xiao-dong1,2, DAI Peng2, WU Jin2, SONG Da-an2, YU Jin-ming3. Weekly recombinant human endostatin as a hypoxic tumor cell radio sensitizer combined with radiotherapy for non-small-cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(11): 108-.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd